Drug development

#Biotechnology #Biotherapeutics #Drug development #Drug discovery #Therapeutics

1910 Genetics launches to accelerate therapeutics design

Biotechnology company integrating artificial intelligence (AI), computation and biological automation to improve drug development, has launched after closing its $22 million Series A funding round. 1910 Genetics’ aim is to decrease the timeline and cost of drug development, while improving the success rate of getting medicines to patients. 1910 Genetics… Read More

#News

#Biotherapeutics #Coronavirus #Covid-19 #Drug development

Infex filed for UK patent for coronavirus novel therapy design

Infex Therapeutics has filed for a UK patent for a novel therapy designed to tackle all coronavirus strains. The COV-X program targets a protein which is essential for viral replication across a broad spectrum of related coronaviruses, including SARS-CoV-1, MERS-CoV and SARS-CoV-2. If successfully developed, the treatment aims to form… Read More

#Covid-19 #News

#Drug design #Drug development #Drug discovery #Neuroscience #Parkinson's

IRICoR and Valence collaborate in AI drug design for Parkinson’s

IRICoR, a pan-Canadian drug discovery and research commercialisation centre, Université de Montréal (UdeM), the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Valence Discovery, an emerging leader in AI-enabled drug design, have announced a collaboration focused on the discovery of novel drug candidates for… Read More

#News

#Drug delivery #Drug development #Drug discovery #Research

Russian scientists’ to help create targeted drug delivery capsules

Scientists from MIPT and ITMO University and their colleagues have studied the formation and growth of crystals from simple organic molecules into large associations, which may help create capsules for targeted drug delivery to specific tissues in the human body. The scientific paper was published in the journal Crystal Growth… Read More

#News

#Clinical trials #Covid-19 #Drug development #Drug discovery #Research

Hormone drugs may disarm COVID-19 spike protein

Researchers in the Abramson Cancer Center at the University of Pennsylvania have published a new preclinical study which found hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease. The study, published online in Cell Press’s iScience, showed how two… Read More

#Covid-19 #News

#Drug candidates #Drug delivery #Drug development #Drug discovery #Gene therapy

Ilya’s ILP100 gene therapy speeds up healing by six days on average

Clinical stage gene therapy company, Ilya Pharma, has released further results from the first in human (FIH) trial of ILP100 for treating difficult and chronic wounds. ILP100 represents a new-in-class drug candidate, engineering Limosilactobacillus reuteri bacteria to produce and release the key human chemokine CXCL12 at the wound site. After delivery, ILP100 enhances the healing properties of immune cells in the… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trial #Data #Drug development #Drug discovery #Report

Report promotes the use of synthetic data in clinical trials

Phesi, provider of AI-powered clinical development analytics products and solutions, and Accenture, a services and consulting company, have released the first of a series of reports exploring the use of synthetic data in clinical development. In recent years, the volume of data created through clinical trials and electronic patient records… Read More

#News

#Antibodies #Biologics #Covid-19 #Drug development #Drug discovery #Online focus

IONTAS has identified novel SARS-CoV-2 neutralising antibodies

IONTAS and FairJourney Biologics have identified neutralising antibodies, which bind to multiple emerging SARS-CoV-2 variants. The results, generated from a combination of phage display technology and B-cell receptor repertoire sequencing of hospitalised COVID-19 patients, identified potent neutralising antibodies with distinct mechanisms of action. Based on this approach, the company has… Read More

#News

#Biotechnology #Covid-19 #Drug development

Molecular ‘cookie cutter’ method could provide key for COVID drug discovery

Researchers from the University of Birmingham are working to isolate and extract the COVID-19 encounter complex in a form that is stable enough for identification of target sites for future anti-viral drugs. The encounter complex is formed when the COVID-19 spike latches onto a binding site on an ACE-2 receptor,… Read More

#News

#Biopharmaceuticals #Drug development #Drug discovery #Oncology

LDC and Cumulus Oncology announce collaboration

The Lead Discovery Centre (LDC) and Cumulus Oncology are collaborating to enable the two organisations to accelerate the discovery and development of novel oncology therapies. LDC contributes drug discovery expertise and a team of scientists with the ability to develop assets modulating a range of oncology targets derived from its… Read More

#News

#Biopharmaceutical #Drug development #Drug discovery #mRNA

Evotec and Takeda enter RNA targeting drug discovery alliance

Evotec has entered into a multi-RNA target alliance with Takeda Pharmaceutical with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches. Evotec and Takeda will jointly identify and develop small molecules targeting a range of… Read More

#News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Podcast #Sartorius

Advances in cell and protein analysis for virology research

This free to listen podcast and DDW exclusive, features Dr Hongshan Li, Applications Manager, Sartorius, discussing advances in cell and protein analysis for virology research. This episode only available to download here, examines virology research – what’s currently happening in the sector and how new advances in technology are helping push forward… Read More

#Podcasts

#Cancer research #Drug development #Institute of Cancer Research #Oncology #Therapeutics

Resistance-busting ICR drug enters clinical trial

The Institute of Cancer Research (ICR), London, has discovered a drug that could counteract drug resistance in patients with cancers including acute myeloid leukaemia. It has entered a Phase I clinical trial at The Royal Marsden NHS Foundation Trust. The drug, now called EP0042, is a dual inhibitor of cancer-driving… Read More

#Cancer Research #Editor's Choice #News

#Biotechnology #Drug delivery #Drug development #Events

Join NanoTemper Technologies’ Prometheus Panta tour

NanoTemper Technologies will be running a case study and walk through of Prometheus Panta. Join the company on 30 March to learn how to make formulation workflow more efficient with multi-parameter stability characterisation. This event will provide new perspectives on data and will look at how running thermal unfolding, particle… Read More

#News

#Biologics / Biotechnology #Drug development #Events #Exhibition

SLAS Europe 2021 registration now open

Registration is now open for the SLAS Europe 2021 Hybrid Conference and Exhibition, which aims to connect people and advance science. There are flexible rates and registration options for both the in-person events in Vienna and Austria, and online, from June 22-25, 2021. SLAS Europe 2021 Hybrid offers a programme… Read More

#News